title: Comment on: TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013;36:1749-1757.
authors.affiliation: Corresponding author: James C. Baldi, chris.baldi@otago.ac.nz.
authors.forename: James C
authors.initials: JC
authors.lastname: Baldi
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Manning
authors.forename: Paul L
authors.initials: PL
authors.lastname: Hofman
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Walker
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology*; D050417:Insulin-Secreting Cells / Q000502:physiology*; D008019:Life Style; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D013844:Thiazoles; D008687:Metformin